Program
Oligonucleotides, Antisense
Also written as “NIO752” and “antisense oligonucleotide”.
In Novartis's pipeline, Tau antisense oligonucleotide
. Its studies are mostly in Supranuclear Palsy, Progressive · Alzheimer Disease, led by Novartis.
Furthest: phase 2, since Oct 5, 20263 company-led studies, 2 open or runningNext primary completion: Mar 26, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 32 open or running | phase 2since Oct 5, 2026 | Aug 25, 2020 | Mar 26, 2029phase 2 · NCT07868328 |
- Named in Novartis’s own pipeline as
NIO752
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2020First study: phase 1 study in Supranuclear Palsy, ProgressiveFirst studyNCT04539041 · 59 enrolled · United States, Canada, Germany and more
- Jul 11, 2022Phase 1 study in Alzheimer DiseaseNCT05469360 · 38 enrolled · Finland, France, Spain and more
- Oct 5, 2026Phase 2 study in Supranuclear Palsy, ProgressivePhase 2 reachedNCT07868328 · 48 planned
Ahead
- Mar 26, 2029Primary completion: phase 2 study in Supranuclear Palsy, ProgressiveNCT07868328
TargetBeta
“Tau antisense oligonucleotide”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07868328Supranuclear Palsy, Progressive | 2 | Not yet recruiting | Mar 26, 2029 | 48 |
| NCT05469360Alzheimer Disease · Finland, France, Spain and more | 1 | Active, not recruiting | Jul 30, 2026 | 38 |
| NCT04539041Supranuclear Palsy, Progressive · United States, Canada, Germany and more | 1 | Completed | Oct 17, 2024 | 59 |
How it is read
Names in the registry
- “NIO752”, 6 entries
- “antisense oligonucleotide”, 1 entry
Codes read as this program: NIO752.
Conditions, from the studies’ own filings
- Supranuclear Palsy, Progressive, 2 studies
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.